September 13, 2021 -- Artificial intelligence-powered biotech and drug discovery platform AbCellera has acquired biotechnology firm TetraGenetics.
TetraGenetics offers a platform that generates recombinant human ion channels and transmembrane proteins such as G protein-coupled receptors. The acquisition will allow AbCellera to integrate TetraGenetics' biotechnology into its drug discovery efforts, it said.
Financial details of the acquisition were not disclosed.